首页 > 最新文献

Acta Pharmaceutica Sinica. B最新文献

英文 中文
Clostridium perfringens alpha toxin drives pathological NETosis via immature neutrophil mobilization and functional reprogramming 产气荚膜梭菌α毒素通过未成熟中性粒细胞动员和功能重编程驱动病理性NETosis。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-09-12 DOI: 10.1016/j.apsb.2025.09.011
Pinnan Zhao , Zongcheng Li , Chaoyan Yao , Yi Zhou , Yangyihua Zhou , Ning Shi , Jie Wang , Can Xu , Peixun Gao , Xuechen Yang , Liang Zhang , Yaowei Ma , Jiannan Feng , Chunxia Qiao , Xinying Li , Changyan Li , Longlong Luo , Xiang Gao
Clostridium perfringens alpha toxin (CPA), a zinc-dependent phospholipase C, is a key virulence factor in gas gangrene. While its membrane-disrupting cytotoxicity is well characterized, its capacity to modulate neutrophil function and promote pathological inflammation is poorly defined. Here, we show that CPA induces neutrophil extracellular trap (NETs) formation by mobilizing and functionally reprogramming immature neutrophils. In a murine model, CPA challenge caused dose-dependent mortality and multi-organ injury, driven by a dramatic expansion of a pro-NETotic immature neutrophil subset identified by single-cell RNA sequencing. This was confirmed by elevated systemic NETs markers and extensive NETs deposition in damaged tissues. Mechanistically, CPA directly triggered reactive oxygen species (ROS)-dependent, peptidylarginine deiminase 4 (PAD4)-mediated NETosis in both murine and human neutrophils, revealing a conserved pathogenic mechanism. Importantly, therapeutic targeting of the NETotic pathway—via PAD4 inhibition, (Deoxyribonuclease I) DNase I treatment, or neutrophil depletion—significantly reduced tissue damage and improved survival. These findings identify a CPA–neutrophil–NETs axis as a central driver of immunopathology. Our study reframes CPA from a classical cytolysin to a potent immunomodulatory toxin that hijacks neutrophil fate. Our findings validate the NETotic pathway as a critical therapeutic target, providing a strong rationale for developing host-directed therapies—potentially in combination with toxin-neutralizing agents—to combat severe toxin-driven diseases.
产气荚膜梭菌α毒素(CPA)是一种锌依赖性磷脂酶C,是气性坏疽的关键毒力因子。虽然其膜破坏细胞毒性已被很好地表征,但其调节中性粒细胞功能和促进病理性炎症的能力尚不清楚。在这里,我们发现CPA通过动员和功能重编程未成熟的中性粒细胞诱导中性粒细胞胞外陷阱(NETs)的形成。在小鼠模型中,CPA攻击引起剂量依赖性死亡和多器官损伤,这是由单细胞RNA测序鉴定的亲netotic未成熟中性粒细胞亚群的急剧扩张所驱动的。全身NETs标记物升高和受损组织中广泛的NETs沉积证实了这一点。在机制上,CPA直接触发了小鼠和人中性粒细胞中活性氧(ROS)依赖的肽精氨酸脱亚胺酶4 (PAD4)介导的NETosis,揭示了一个保守的致病机制。重要的是,通过PAD4抑制、(脱氧核糖核酸酶I) dna酶I治疗或中性粒细胞消耗,靶向NETotic通路的治疗可显著减少组织损伤并提高生存率。这些发现确定了cpa -中性粒细胞- nets轴是免疫病理的中心驱动因素。我们的研究将CPA从一种经典的细胞溶解素重新定义为一种劫持中性粒细胞命运的强效免疫调节毒素。我们的研究结果证实了NETotic通路是一个关键的治疗靶点,为开发宿主导向疗法(可能与毒素中和剂联合使用)提供了强有力的理论依据,以对抗严重的毒素驱动疾病。
{"title":"Clostridium perfringens alpha toxin drives pathological NETosis via immature neutrophil mobilization and functional reprogramming","authors":"Pinnan Zhao ,&nbsp;Zongcheng Li ,&nbsp;Chaoyan Yao ,&nbsp;Yi Zhou ,&nbsp;Yangyihua Zhou ,&nbsp;Ning Shi ,&nbsp;Jie Wang ,&nbsp;Can Xu ,&nbsp;Peixun Gao ,&nbsp;Xuechen Yang ,&nbsp;Liang Zhang ,&nbsp;Yaowei Ma ,&nbsp;Jiannan Feng ,&nbsp;Chunxia Qiao ,&nbsp;Xinying Li ,&nbsp;Changyan Li ,&nbsp;Longlong Luo ,&nbsp;Xiang Gao","doi":"10.1016/j.apsb.2025.09.011","DOIUrl":"10.1016/j.apsb.2025.09.011","url":null,"abstract":"<div><div><em>Clostridium perfringens</em> alpha toxin (CPA), a zinc-dependent phospholipase C, is a key virulence factor in gas gangrene. While its membrane-disrupting cytotoxicity is well characterized, its capacity to modulate neutrophil function and promote pathological inflammation is poorly defined. Here, we show that CPA induces neutrophil extracellular trap (NETs) formation by mobilizing and functionally reprogramming immature neutrophils. In a murine model, CPA challenge caused dose-dependent mortality and multi-organ injury, driven by a dramatic expansion of a pro-NETotic immature neutrophil subset identified by single-cell RNA sequencing. This was confirmed by elevated systemic NETs markers and extensive NETs deposition in damaged tissues. Mechanistically, CPA directly triggered reactive oxygen species (ROS)-dependent, peptidylarginine deiminase 4 (PAD4)-mediated NETosis in both murine and human neutrophils, revealing a conserved pathogenic mechanism. Importantly, therapeutic targeting of the NETotic pathway—<em>via</em> PAD4 inhibition, (Deoxyribonuclease I) DNase I treatment, or neutrophil depletion—significantly reduced tissue damage and improved survival. These findings identify a CPA–neutrophil–NETs axis as a central driver of immunopathology. Our study reframes CPA from a classical cytolysin to a potent immunomodulatory toxin that hijacks neutrophil fate. Our findings validate the NETotic pathway as a critical therapeutic target, providing a strong rationale for developing host-directed therapies—potentially in combination with toxin-neutralizing agents—to combat severe toxin-driven diseases.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 879-899"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine learning empowered formulation design, optimization and characterization of nanoparticulate drug delivery systems: Current applications, challenges, and future perspectives 机器学习增强了纳米颗粒给药系统的配方设计、优化和表征:当前应用、挑战和未来前景。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-12-10 DOI: 10.1016/j.apsb.2025.12.011
Chunyan Shen , Mengyan Zhang , Meiting Lu , Errong Chang , Ziting Gao , Weikang Ban , Qiang Liu , Zhong Zuo , Cuiping Jiang
Nanoparticulate drug delivery systems (NDDS) have revolutionized modern medicine by significantly improving drug targeting, bioavailability, and therapeutic efficacy. Despite the clinical success of over 90 approved nanomedicines, the development of NDDS remains challenging due to the complexity of formulation design, optimization, and characterization processes. Artificial intelligence, particularly machine learning (ML), offers powerful data analytics and predictive capabilities that can address these challenges. This review systematically summarizes recent advances in ML applications across various NDDS formulations, including polymeric nanoparticles, lipid nanoparticles, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, nanosuspensions, lipid-based hybrid NDDS, self-emulsifying drug delivery systems, niosomes, and nanocrystals. We also summarize how ML algorithms could help predict critical quality attributes of NDDS, such as particle size, shape, surface properties, drug encapsulation efficiency, drug loading efficiency, drug release behavior, and stability. Furthermore, we discuss existing challenges and prospects for the formulation development empowered by ML in NDDS. In conclusion, this review provides a comprehensive overview of the transformative potential of ML in improving the formulation development of nanomedicines, ultimately accelerating their clinical translation.
纳米颗粒给药系统(NDDS)通过显著提高药物靶向性、生物利用度和治疗效果,彻底改变了现代医学。尽管已经有超过90种纳米药物获得了临床成功,但由于配方设计、优化和表征过程的复杂性,NDDS的开发仍然具有挑战性。人工智能,特别是机器学习(ML),提供了强大的数据分析和预测能力,可以应对这些挑战。本文系统总结了各种NDDS配方中ML应用的最新进展,包括聚合物纳米颗粒、脂质纳米颗粒、脂质体、固体脂质纳米颗粒、纳米结构脂质载体、纳米乳液、纳米悬浮液、脂质基杂化NDDS、自乳化药物传递系统、乳质体和纳米晶体。我们还总结了ML算法如何帮助预测NDDS的关键质量属性,如粒径、形状、表面性质、药物包封效率、药物装载效率、药物释放行为和稳定性。此外,我们还讨论了ML在NDDS中支持的配方开发的现有挑战和前景。总之,本综述全面概述了机器学习在改善纳米药物配方开发,最终加速其临床转化方面的变革潜力。
{"title":"Machine learning empowered formulation design, optimization and characterization of nanoparticulate drug delivery systems: Current applications, challenges, and future perspectives","authors":"Chunyan Shen ,&nbsp;Mengyan Zhang ,&nbsp;Meiting Lu ,&nbsp;Errong Chang ,&nbsp;Ziting Gao ,&nbsp;Weikang Ban ,&nbsp;Qiang Liu ,&nbsp;Zhong Zuo ,&nbsp;Cuiping Jiang","doi":"10.1016/j.apsb.2025.12.011","DOIUrl":"10.1016/j.apsb.2025.12.011","url":null,"abstract":"<div><div>Nanoparticulate drug delivery systems (NDDS) have revolutionized modern medicine by significantly improving drug targeting, bioavailability, and therapeutic efficacy. Despite the clinical success of over 90 approved nanomedicines, the development of NDDS remains challenging due to the complexity of formulation design, optimization, and characterization processes. Artificial intelligence, particularly machine learning (ML), offers powerful data analytics and predictive capabilities that can address these challenges. This review systematically summarizes recent advances in ML applications across various NDDS formulations, including polymeric nanoparticles, lipid nanoparticles, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, nanosuspensions, lipid-based hybrid NDDS, self-emulsifying drug delivery systems, niosomes, and nanocrystals. We also summarize how ML algorithms could help predict critical quality attributes of NDDS, such as particle size, shape, surface properties, drug encapsulation efficiency, drug loading efficiency, drug release behavior, and stability. Furthermore, we discuss existing challenges and prospects for the formulation development empowered by ML in NDDS. In conclusion, this review provides a comprehensive overview of the transformative potential of ML in improving the formulation development of nanomedicines, ultimately accelerating their clinical translation.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 665-685"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intratumoral immune-microbial crosstalk shaped by tumor cell-derived extracellular vesicles encapsulating berberine boosts lung cancer immunotherapy 肿瘤细胞源性细胞外囊泡包封小檗碱形成的肿瘤内免疫-微生物串扰促进肺癌免疫治疗。
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2025-12-13 DOI: 10.1016/j.apsb.2025.12.014
Jingjing Deng , Wenlong Kuang , Wenjuan Chen , E. Zhou , Yali Wu , Zimo Yang , Jiangbin Chen , Xinghui Cao , Zhengrong Yin , Jiatong Liu , Minglei Li , Feng Wu , Jinshuo Fan , Mengfei Guo , Yang Jin
The intratumoral microbiome plays a crucial role in cancer progression, prompting the development of therapies targeting it. However, due to the heterogeneous effects of intratumoral microbes, designing treatments tailored to the unique microecological characteristics of individual tumors poses a significant challenge. Here, we found significant variations in the abundance of five bacterial genera—Lysinibacillus, Stenotrophomonas, Weissella, Comamonas, and Aeromonas—between lung adenocarcinoma (LUAD) and normal tissues by analyzing single-cell transcriptomic datasets. These specific bacterial clusters were significantly associated with immune infiltrates in the tumor microenvironment (TME). After confirming their effects in mouse models, these bacterial taxa were identified as potential therapeutic targets. Through in vitro drug screening assays, berberine was identified as a promising agent that selectively inhibits harmful bacteria while sparing beneficial ones. To address berberine’s low solubility and tumor targeting issues, it was encapsulated into tumor cell-derived extracellular vesicles (EV-ber). Feature analysis demonstrated that EV-ber shifted the intratumoral microbiome profile toward an anti-tumor phenotype and enhanced anti-tumor immunity in the TME. Furthermore, EV-ber administration inhibited LUAD growth, impaired LUAD metastatic ability, and boosted the effectiveness of anti-PD-L1 immunotherapy in mouse models. In conclusion, this work demonstrates the potential of personalized intratumoral microbial re-education strategies in LUAD therapy.
肿瘤内微生物组在癌症进展中起着至关重要的作用,促进了针对它的治疗方法的发展。然而,由于肿瘤内微生物的异质性效应,针对单个肿瘤独特的微生态特征设计治疗方案是一项重大挑战。在这里,通过分析单细胞转录组数据集,我们发现肺腺癌(LUAD)和正常组织中五种细菌属(溶杆菌、窄养单胞菌、魏塞尔菌、单胞菌和气单胞菌)的丰度存在显著差异。这些特定的细菌簇与肿瘤微环境(TME)的免疫浸润显著相关。在小鼠模型中证实了它们的作用后,这些细菌分类群被确定为潜在的治疗靶点。通过体外药物筛选试验,发现小檗碱具有选择性抑制有害细菌,保留有益细菌的作用。为了解决小檗碱的低溶解度和肿瘤靶向性问题,将其包裹在肿瘤细胞源性细胞外囊泡(EV-ber)中。特征分析表明,EV-ber将肿瘤内微生物组谱向抗肿瘤表型转移,并增强了TME的抗肿瘤免疫。此外,在小鼠模型中,给药EV-ber抑制LUAD生长,损害LUAD转移能力,并提高抗pd - l1免疫治疗的有效性。总之,这项工作证明了LUAD治疗中个性化肿瘤内微生物再教育策略的潜力。
{"title":"Intratumoral immune-microbial crosstalk shaped by tumor cell-derived extracellular vesicles encapsulating berberine boosts lung cancer immunotherapy","authors":"Jingjing Deng ,&nbsp;Wenlong Kuang ,&nbsp;Wenjuan Chen ,&nbsp;E. Zhou ,&nbsp;Yali Wu ,&nbsp;Zimo Yang ,&nbsp;Jiangbin Chen ,&nbsp;Xinghui Cao ,&nbsp;Zhengrong Yin ,&nbsp;Jiatong Liu ,&nbsp;Minglei Li ,&nbsp;Feng Wu ,&nbsp;Jinshuo Fan ,&nbsp;Mengfei Guo ,&nbsp;Yang Jin","doi":"10.1016/j.apsb.2025.12.014","DOIUrl":"10.1016/j.apsb.2025.12.014","url":null,"abstract":"<div><div>The intratumoral microbiome plays a crucial role in cancer progression, prompting the development of therapies targeting it. However, due to the heterogeneous effects of intratumoral microbes, designing treatments tailored to the unique microecological characteristics of individual tumors poses a significant challenge. Here, we found significant variations in the abundance of five bacterial genera—<em>Lysinibacillus</em>, <em>Stenotrophomonas</em>, <em>Weissella</em>, <em>Comamonas</em>, and <em>Aeromonas</em>—between lung adenocarcinoma (LUAD) and normal tissues by analyzing single-cell transcriptomic datasets. These specific bacterial clusters were significantly associated with immune infiltrates in the tumor microenvironment (TME). After confirming their effects in mouse models, these bacterial taxa were identified as potential therapeutic targets. Through <em>in vitro</em> drug screening assays, berberine was identified as a promising agent that selectively inhibits harmful bacteria while sparing beneficial ones. To address berberine’s low solubility and tumor targeting issues, it was encapsulated into tumor cell-derived extracellular vesicles (EV-ber). Feature analysis demonstrated that EV-ber shifted the intratumoral microbiome profile toward an anti-tumor phenotype and enhanced anti-tumor immunity in the TME. Furthermore, EV-ber administration inhibited LUAD growth, impaired LUAD metastatic ability, and boosted the effectiveness of anti-PD-L1 immunotherapy in mouse models. In conclusion, this work demonstrates the potential of personalized intratumoral microbial re-education strategies in LUAD therapy.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 1090-1115"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cover Story 封面故事
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-02-01 Epub Date: 2026-02-05 DOI: 10.1016/S2211-3835(26)00009-2
{"title":"Cover Story","authors":"","doi":"10.1016/S2211-3835(26)00009-2","DOIUrl":"10.1016/S2211-3835(26)00009-2","url":null,"abstract":"","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Page xii"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146186670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Palmitoylation of Tfr1 enhances platelet ferroptosis and liver injury in heat stroke Tfr1棕榈酰化增强中暑患者血小板铁下沉和肝损伤
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01 Epub Date: 2025-10-24 DOI: 10.1016/j.apsb.2025.10.027
Qiyuan An , Riqing Wei , Zhicheng Huang , Youyong Tang , Minghao Wang , Sixiao He , Kaihua Huang , Zhifeng Liu , Meimei Zhang , Ru Li , Junhao Huang , Keying Zhang , Jingjing Ji , Liwei Xie , Qiang Ma
Heat stroke (HS) is a severe medical emergency characterized by coagulation and high mortality due to organ injury. This study identifies a novel mechanism in which platelet ferroptosis, driven by transferrin receptor 1 (Tfr1) palmitoylation, significantly contributes to liver injury in HS. Our findings reveal a strong inverse correlation between platelet count and organ damage, especially liver injury, as well as mortality rates. Using murine models, we demonstrate that inhibiting Tfr1-mediated ferroptosis in platelets mitigates thrombocytopenia and decreases Interleukin-1β (IL-1β) secretion, thereby improving liver function and survival outcomes. This research highlights Tfr1 palmitoylation as a critical factor in iron transport within platelets, with the palmitoylation inhibitor 2-bromopalmitate (2BP) effectively reducing total iron, Fe2+, lipid ROS, 4-hydroxynonenal (4-HNE), and cell cytotoxicity under heat stress. These results suggest that targeting Tfr1 palmitoylation-dependent ferroptosis in platelets offers a novel therapeutic strategy for treating HS-induced thrombocytopenia and liver injury.
中暑是一种严重的医学急症,以器官损伤引起的凝血和高死亡率为特征。本研究发现了一种新的机制,即由转铁蛋白受体1 (Tfr1)棕榈酰化驱动的血小板铁下沉,显著促进了HS的肝损伤。我们的研究结果揭示了血小板计数与器官损伤,特别是肝损伤,以及死亡率之间强烈的负相关。通过小鼠模型,我们证明抑制血小板中tfr1介导的铁凋亡可以减轻血小板减少症,减少白细胞介素-1β (IL-1β)的分泌,从而改善肝功能和生存结果。本研究强调Tfr1棕榈酰化是血小板内铁转运的关键因素,棕榈酰化抑制剂2-溴铝酸盐(2BP)可有效降低热应激下的总铁、Fe2+、脂质ROS、4-羟基壬烯醛(4-HNE)和细胞毒性。这些结果表明,靶向血小板中Tfr1棕榈酰化依赖性铁凋亡为治疗hs诱导的血小板减少症和肝损伤提供了一种新的治疗策略。
{"title":"Palmitoylation of Tfr1 enhances platelet ferroptosis and liver injury in heat stroke","authors":"Qiyuan An ,&nbsp;Riqing Wei ,&nbsp;Zhicheng Huang ,&nbsp;Youyong Tang ,&nbsp;Minghao Wang ,&nbsp;Sixiao He ,&nbsp;Kaihua Huang ,&nbsp;Zhifeng Liu ,&nbsp;Meimei Zhang ,&nbsp;Ru Li ,&nbsp;Junhao Huang ,&nbsp;Keying Zhang ,&nbsp;Jingjing Ji ,&nbsp;Liwei Xie ,&nbsp;Qiang Ma","doi":"10.1016/j.apsb.2025.10.027","DOIUrl":"10.1016/j.apsb.2025.10.027","url":null,"abstract":"<div><div>Heat stroke (HS) is a severe medical emergency characterized by coagulation and high mortality due to organ injury. This study identifies a novel mechanism in which platelet ferroptosis, driven by transferrin receptor 1 (Tfr1) palmitoylation, significantly contributes to liver injury in HS. Our findings reveal a strong inverse correlation between platelet count and organ damage, especially liver injury, as well as mortality rates. Using murine models, we demonstrate that inhibiting Tfr1-mediated ferroptosis in platelets mitigates thrombocytopenia and decreases Interleukin-1<em>β</em> (IL-1<em>β</em>) secretion, thereby improving liver function and survival outcomes. This research highlights Tfr1 palmitoylation as a critical factor in iron transport within platelets, with the palmitoylation inhibitor 2-bromopalmitate (2BP) effectively reducing total iron, Fe<sup>2+</sup>, lipid ROS, 4-hydroxynonenal (4-HNE), and cell cytotoxicity under heat stress. These results suggest that targeting Tfr1 palmitoylation-dependent ferroptosis in platelets offers a novel therapeutic strategy for treating HS-induced thrombocytopenia and liver injury.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 1","pages":"Pages 270-286"},"PeriodicalIF":14.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145941392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structure-guided design of picomolar-level macrocyclic TRPC5 channel inhibitors with antidepressant activity 具有抗抑郁活性的皮摩尔级大环TRPC5通道抑制剂的结构引导设计
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01 Epub Date: 2025-10-27 DOI: 10.1016/j.apsb.2025.10.028
Tong Che , Yixiang Chen , Xinyu Cheng , Han Hu , Xiaoyun Wu , Yuting Zhang , Xiaoqiang Yang , Yinzhen Liu , Hui Liu , Weiwei Nan , Shuangyan Wan , Mingxing Yang , Bo Zeng , Jian Li , Jin Zhang , Bing Xiong
Recent advances in ion channel structural biology have enhanced structure-based drug design, yet lipid-occupied binding pockets—often large and flat—remain a major hurdle for developing selective small molecules. TRPC5, a brain-enriched channel regulating depression and anxiety, is a promising therapeutic target, but current preclinical candidates suffer from moderate off-target effects. To address this, we designed macrocyclic TRPC5 inhibitors using structure-guided macrocyclization, overcoming lipid-binding site challenges. Among these, JDIC-127 exhibited unprecedented potency with IC50 of 374 pmol/L—200-fold more potent than HC-070—and exceptional selectivity. Its specificity arises from interactions with unique structural features near the S5 and S6 helices of TRPC5, minimizing activity against related TRPC channels and other ion channels. This selective inhibition aligns with preclinical evidence supporting JDIC-127's potential in treating neuropsychiatric disorders. The study demonstrates how macrocycles stabilize ligand conformations, enhance affinity, and achieve selectivity in lipid-dominated binding sites. It also highlights the synergy between macrocyclic design, cryo-EM, and computational modeling to address longstanding obstacles in ion channel drug discovery. JDIC-127 serves as a proof-of-concept for the application of macrocyclization in ion channel pharmacology, offering a roadmap for developing innovative therapeutics targeting TRP channels and beyond, with implications for a wide range of diseases.
离子通道结构生物学的最新进展增强了基于结构的药物设计,然而脂质占据的结合袋——通常又大又平——仍然是开发选择性小分子的主要障碍。TRPC5是一种调节抑郁和焦虑的大脑富集通道,是一种很有希望的治疗靶点,但目前的临床前候选药物存在中度脱靶效应。为了解决这个问题,我们使用结构引导的大环化设计了大环TRPC5抑制剂,克服了脂质结合位点的挑战。其中,JDIC-127的IC50值为374 pmol/ l,是hc -070的200倍,具有较强的选择性。其特异性源于与TRPC5的S5和S6螺旋附近的独特结构特征相互作用,最大限度地降低了对相关TRPC通道和其他离子通道的活性。这种选择性抑制与临床前证据一致,支持JDIC-127在治疗神经精神疾病方面的潜力。该研究展示了大环如何稳定配体构象,增强亲和力,并在脂质主导的结合位点实现选择性。它还强调了大环设计、低温电镜和计算建模之间的协同作用,以解决离子通道药物发现中的长期障碍。JDIC-127为大环化在离子通道药理学中的应用提供了概念验证,为开发针对TRP通道及其他通道的创新治疗方法提供了路线图,对多种疾病具有重要意义。
{"title":"Structure-guided design of picomolar-level macrocyclic TRPC5 channel inhibitors with antidepressant activity","authors":"Tong Che ,&nbsp;Yixiang Chen ,&nbsp;Xinyu Cheng ,&nbsp;Han Hu ,&nbsp;Xiaoyun Wu ,&nbsp;Yuting Zhang ,&nbsp;Xiaoqiang Yang ,&nbsp;Yinzhen Liu ,&nbsp;Hui Liu ,&nbsp;Weiwei Nan ,&nbsp;Shuangyan Wan ,&nbsp;Mingxing Yang ,&nbsp;Bo Zeng ,&nbsp;Jian Li ,&nbsp;Jin Zhang ,&nbsp;Bing Xiong","doi":"10.1016/j.apsb.2025.10.028","DOIUrl":"10.1016/j.apsb.2025.10.028","url":null,"abstract":"<div><div>Recent advances in ion channel structural biology have enhanced structure-based drug design, yet lipid-occupied binding pockets—often large and flat—remain a major hurdle for developing selective small molecules. TRPC5, a brain-enriched channel regulating depression and anxiety, is a promising therapeutic target, but current preclinical candidates suffer from moderate off-target effects. To address this, we designed macrocyclic TRPC5 inhibitors using structure-guided macrocyclization, overcoming lipid-binding site challenges. Among these, JDIC-127 exhibited unprecedented potency with IC<sub>50</sub> of 374 pmol/L—200-fold more potent than HC-070—and exceptional selectivity. Its specificity arises from interactions with unique structural features near the S5 and S6 helices of TRPC5, minimizing activity against related TRPC channels and other ion channels. This selective inhibition aligns with preclinical evidence supporting JDIC-127's potential in treating neuropsychiatric disorders. The study demonstrates how macrocycles stabilize ligand conformations, enhance affinity, and achieve selectivity in lipid-dominated binding sites. It also highlights the synergy between macrocyclic design, cryo-EM, and computational modeling to address longstanding obstacles in ion channel drug discovery. JDIC-127 serves as a proof-of-concept for the application of macrocyclization in ion channel pharmacology, offering a roadmap for developing innovative therapeutics targeting TRP channels and beyond, with implications for a wide range of diseases.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 1","pages":"Pages 371-386"},"PeriodicalIF":14.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145941529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unraveling the FGFR–RNA splicing axis: Mechanisms, oncogenic crosstalks and innovations for therapeutic purpose 揭示FGFR-RNA剪接轴:机制,致癌串扰和治疗目的的创新
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01 Epub Date: 2025-12-01 DOI: 10.1016/j.apsb.2025.11.031
Xuquan Xian , Ruyi Gong , Shunzi Rong , Zhihao Zhang , Fengtong Jia , Lin Li , Zhengguo Chen , Beatrice Eymin , Tao Jia
Fibroblast growth factor receptor (FGFR) signaling is a pivotal regulator of tumor progression, driving cell proliferation, survival, metastasis, and therapeutic resistance across diverse cancer types. RNA alternative splicing profoundly shapes FGFR isoform diversity, endowing tumors with heterogeneity and adaptability to targeted interventions. While significant progress has been made in identifying splicing regulators that govern FGFR pre-mRNA processing, the extracellular cues influencing this process and the reciprocal impact of FGFR signaling pathway on global splicing networks remain underexplored. This review provides a comprehensive overview of the bidirectional interplay linking FGFR signaling and RNA splicing in cancer. Mechanistically, we first detail how FGFR mutations, epigenetic modifications, and crosstalks with oncogenic pathways reprogram splicing to generate tumor-specific FGFR splice variants. We then systematically classify distinct FGFR isoforms and delineate how they contribute to main cancer hallmarks, underscoring the central role of the FGFR–splicing axis in driving tumor plasticity, heterogeneity and adaptive progression. Conversely, we also examine how FGFR signaling modulates RNA splicing programs beyond FGFR itself, reshaping global splicing events that contribute to tumorigenesis, an emerging and still largely unexplored area of cancer biology. From therapeutic perspective, we highlight emerging strategies targeting the axis. Notably, FGFR splicing isoform-directed radiopharmaceuticals hold great promise for patient stratification and biomarker-directed theranostics, providing a precise approach to identify aggressive tumors and guide tailored interventions. As well, complementary approaches, including CRISPR/Cas9-based splicing modulation and long non-coding RNAs-targeted therapies, further expand the toolbox for isoform-specific intervention. Moreover, integrating splicing modulators with FGFR TKIs may overcome drug resistance. Understanding the intricate interplay between FGFR signaling and RNA splicing will not only advance biomarker-guided therapeutic development but also provide a novel framework to counteract tumor adaptability, ultimately improving outcomes in FGFR-driven malignancies.
成纤维细胞生长因子受体(FGFR)信号是肿瘤进展、驱动细胞增殖、存活、转移和多种癌症治疗抵抗的关键调节因子。RNA选择性剪接深刻地塑造了FGFR异构体的多样性,赋予肿瘤异质性和靶向干预的适应性。虽然在确定控制FGFR前mrna加工的剪接调节因子方面取得了重大进展,但影响这一过程的细胞外线索以及FGFR信号通路对全球剪接网络的相互影响仍未得到充分探索。本文综述了FGFR信号和RNA剪接在癌症中的双向相互作用。在机制上,我们首先详细介绍了FGFR突变、表观遗传修饰和与致癌途径的串扰如何重编程剪接以产生肿瘤特异性FGFR剪接变体。然后,我们系统地对不同的FGFR亚型进行分类,并描述它们如何促进主要的癌症特征,强调FGFR剪接轴在驱动肿瘤可塑性、异质性和适应性进展中的核心作用。相反,我们还研究了FGFR信号如何调节FGFR本身以外的RNA剪接程序,重塑有助于肿瘤发生的全局剪接事件,这是癌症生物学中一个新兴且仍未被探索的领域。从治疗的角度来看,我们强调针对轴的新兴策略。值得注意的是,FGFR剪接同种异构体定向放射药物在患者分层和生物标志物定向治疗方面具有很大的前景,提供了一种精确的方法来识别侵袭性肿瘤并指导量身定制的干预措施。此外,互补的方法,包括基于CRISPR/ cas9的剪接调制和长链非编码rna靶向治疗,进一步扩大了同种异型特异性干预的工具箱。此外,将剪接调节剂与FGFR TKIs结合可能克服耐药性。了解FGFR信号传导和RNA剪接之间复杂的相互作用不仅将推进生物标志物引导的治疗开发,还将提供一个新的框架来抵消肿瘤适应性,最终改善FGFR驱动的恶性肿瘤的预后。
{"title":"Unraveling the FGFR–RNA splicing axis: Mechanisms, oncogenic crosstalks and innovations for therapeutic purpose","authors":"Xuquan Xian ,&nbsp;Ruyi Gong ,&nbsp;Shunzi Rong ,&nbsp;Zhihao Zhang ,&nbsp;Fengtong Jia ,&nbsp;Lin Li ,&nbsp;Zhengguo Chen ,&nbsp;Beatrice Eymin ,&nbsp;Tao Jia","doi":"10.1016/j.apsb.2025.11.031","DOIUrl":"10.1016/j.apsb.2025.11.031","url":null,"abstract":"<div><div>Fibroblast growth factor receptor (FGFR) signaling is a pivotal regulator of tumor progression, driving cell proliferation, survival, metastasis, and therapeutic resistance across diverse cancer types. RNA alternative splicing profoundly shapes FGFR isoform diversity, endowing tumors with heterogeneity and adaptability to targeted interventions. While significant progress has been made in identifying splicing regulators that govern FGFR pre-mRNA processing, the extracellular cues influencing this process and the reciprocal impact of FGFR signaling pathway on global splicing networks remain underexplored. This review provides a comprehensive overview of the bidirectional interplay linking FGFR signaling and RNA splicing in cancer. Mechanistically, we first detail how <em>FGFR</em> mutations, epigenetic modifications, and crosstalks with oncogenic pathways reprogram splicing to generate tumor-specific FGFR splice variants. We then systematically classify distinct FGFR isoforms and delineate how they contribute to main cancer hallmarks, underscoring the central role of the FGFR–splicing axis in driving tumor plasticity, heterogeneity and adaptive progression. Conversely, we also examine how FGFR signaling modulates RNA splicing programs beyond FGFR itself, reshaping global splicing events that contribute to tumorigenesis, an emerging and still largely unexplored area of cancer biology. From therapeutic perspective, we highlight emerging strategies targeting the axis. Notably, FGFR splicing isoform-directed radiopharmaceuticals hold great promise for patient stratification and biomarker-directed theranostics, providing a precise approach to identify aggressive tumors and guide tailored interventions. As well, complementary approaches, including CRISPR/Cas9-based splicing modulation and long non-coding RNAs-targeted therapies, further expand the toolbox for isoform-specific intervention. Moreover, integrating splicing modulators with FGFR TKIs may overcome drug resistance. Understanding the intricate interplay between FGFR signaling and RNA splicing will not only advance biomarker-guided therapeutic development but also provide a novel framework to counteract tumor adaptability, ultimately improving outcomes in FGFR-driven malignancies.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 1","pages":"Pages 35-61"},"PeriodicalIF":14.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145941475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An innovative and stable mRNA-LNP microneedle vaccine elicits humoral and multifunctional cellular immune responses 一种创新和稳定的mRNA-LNP微针疫苗引发体液和多功能细胞免疫反应
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01 Epub Date: 2025-10-15 DOI: 10.1016/j.apsb.2025.10.006
Xiaoxuan Hong , Xianfu Li , Xiaolu Han , Jinghu Lou , Yue Li , Jintao Lin , Yi Cheng , Haonan Xing , Hui Zhang , Xiwei Wang , Shuang Zhang , Nan Liu , Zengming Wang , Chunying Cui , Aiping Zheng
During the COVID-19 pandemic, the use of lipid nanoparticles (LNPs) augmented the development of mRNA vaccines. However, their ultralow-temperature storage and transportation requirements, as well as their heavy reliance on injection by professional medical staff, have limited large-scale vaccination in many developing countries. Herein, we developed a simple and widely deployable microneedle (MN) vaccine delivery system (mLNP-man-MN) for mannose-modified LNPs (mLNP-man) loaded with mRNA encoding the SARS-CoV-2 spike receptor-binding domain by utilizing three-dimensional printing and polydimethylsiloxane micro molding methods. This delivery system is composed of a dissolvable polymer mixture that was optimized for high bioactivity by screening formulations in vitro. We have demonstrated that this MN system can maintain the physicochemical properties and bioactivity of the mRNA-LNP complex even when stored at 4 °C for at least one month or at 25 °C for two weeks. Moreover, mLNP-man-MNs target the epidermis and dermis, which are rich in antigen-presenting cells, thereby eliciting effective innate immune responses and inducing robust systemic humoral responses, as well as multifunctional cellular immunity in the spleen. Importantly, the MN system induced a certain level of pulmonary T-cell responses compared to those induced by intramuscular injections, thereby providing some protection against lung invasion by the SARS-CoV-2 pseudovirus in mice.
在COVID-19大流行期间,脂质纳米颗粒(LNPs)的使用促进了mRNA疫苗的开发。然而,它们的超低温储存和运输要求,以及对专业医务人员注射的严重依赖,限制了许多发展中国家的大规模疫苗接种。在此,我们利用三维打印和聚二甲基硅氧烷微成型方法,开发了一种简单且可广泛部署的微针(MN)疫苗递送系统(mLNP-man-MN),用于装载编码SARS-CoV-2刺突受体结合域的mRNA的甘露糖修饰LNPs (mLNP-man)。该给药系统由可溶聚合物混合物组成,该混合物通过体外筛选配方优化为具有高生物活性。我们已经证明,即使在4°C下储存至少一个月或在25°C下储存两周,该MN系统也能保持mRNA-LNP复合物的物理化学性质和生物活性。此外,mLNP-man-MNs靶向富含抗原呈递细胞的表皮和真皮,从而引发有效的先天免疫反应,诱导强大的全身体液反应,以及脾脏的多功能细胞免疫。重要的是,与肌肉注射相比,MN系统诱导了一定水平的肺t细胞反应,从而在一定程度上保护小鼠免受SARS-CoV-2假病毒的肺部入侵。
{"title":"An innovative and stable mRNA-LNP microneedle vaccine elicits humoral and multifunctional cellular immune responses","authors":"Xiaoxuan Hong ,&nbsp;Xianfu Li ,&nbsp;Xiaolu Han ,&nbsp;Jinghu Lou ,&nbsp;Yue Li ,&nbsp;Jintao Lin ,&nbsp;Yi Cheng ,&nbsp;Haonan Xing ,&nbsp;Hui Zhang ,&nbsp;Xiwei Wang ,&nbsp;Shuang Zhang ,&nbsp;Nan Liu ,&nbsp;Zengming Wang ,&nbsp;Chunying Cui ,&nbsp;Aiping Zheng","doi":"10.1016/j.apsb.2025.10.006","DOIUrl":"10.1016/j.apsb.2025.10.006","url":null,"abstract":"<div><div>During the COVID-19 pandemic, the use of lipid nanoparticles (LNPs) augmented the development of mRNA vaccines. However, their ultralow-temperature storage and transportation requirements, as well as their heavy reliance on injection by professional medical staff, have limited large-scale vaccination in many developing countries. Herein, we developed a simple and widely deployable microneedle (MN) vaccine delivery system (mLNP-man-MN) for mannose-modified LNPs (mLNP-man) loaded with mRNA encoding the SARS-CoV-2 spike receptor-binding domain by utilizing three-dimensional printing and polydimethylsiloxane micro molding methods. This delivery system is composed of a dissolvable polymer mixture that was optimized for high bioactivity by screening formulations <em>in vitro</em>. We have demonstrated that this MN system can maintain the physicochemical properties and bioactivity of the mRNA-LNP complex even when stored at 4 °C for at least one month or at 25 °C for two weeks. Moreover, mLNP-man-MNs target the epidermis and dermis, which are rich in antigen-presenting cells, thereby eliciting effective innate immune responses and inducing robust systemic humoral responses, as well as multifunctional cellular immunity in the spleen. Importantly, the MN system induced a certain level of pulmonary T-cell responses compared to those induced by intramuscular injections, thereby providing some protection against lung invasion by the SARS-CoV-2 pseudovirus in mice.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 1","pages":"Pages 503-521"},"PeriodicalIF":14.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145941497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineered cyclic peptide targeting ITGA5 disrupts tumor–stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma 靶向ITGA5的工程化环肽破坏肿瘤-基质相互作用以克服胰腺导管腺癌的结缔组织增生和耐药性
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01 Epub Date: 2025-10-24 DOI: 10.1016/j.apsb.2025.10.022
Deby Fajar Mardhian , Kunal P. Pednekar , Ahmed G. Hemdan , Praneeth Reddy Kuninty , Saadia A. Karim , Sabine de Winter , Josbert M. Metselaar , Jennifer P. Morton , Jai Prakash
The tumor–stroma interaction contributes to the aggressive and resistance nature of pancreatic ductal adenocarcinoma (PDAC), leading to treatment failure. Cancer-associated fibroblasts (CAFs), a key cell type in the stroma, produce abundant extracellular matrix (ECM) and exhibit crosstalk with cancer cells inducing chemoresistance. In this study, we designed a cyclic peptide (cyAV3.3) targeting integrin α5 (ITGA5) to disrupt CAF-induced desmoplasia and crosstalk with cancer cells. In vitro, cyAV3.3 inhibited the differentiation of pancreatic stellate cells into CAFs and reduced ECM production. In 3D co-cultured human spheroid models, the peptide decreased markers of resistance (ABCG1, BCL2, CXCR4), stemness (WNT1, CD44) and ECM remodeling (COL1A1, MMP2/9, LOX) and enhanced gemcitabine efficacy. In vivo, radiolabeled cyAV3.3 exhibited high tumor accumulation and retention following parenteral injections in a co-injection xenograft tumor model. Intriguingly, combination of cyAV3.3 with gemcitabine resulted in improved therapeutic efficacy of gemcitabine in co-injection xenograft and genetically engineered LSL-KrasG12D/+ LSL-Trp53R172H/+ Pdx1-Cre (KPC) PDAC models. These effects were attributed to reduced desmoplasia, vasculature compression and enhanced infiltration of cytotoxic T cells and apoptosis. This study presents a novel cyclic peptide inhibiting ITGA5-mediated tumor–stroma interaction and thereby reduce desmoplasia and resistance, ultimately enhancing chemotherapy efficacy in PDAC.
肿瘤-基质相互作用导致胰腺导管腺癌(PDAC)具有侵袭性和耐药性,导致治疗失败。癌症相关成纤维细胞(CAFs)是间质中的一种关键细胞类型,可产生丰富的细胞外基质(ECM),并与癌细胞发生串扰,诱导化疗耐药。在本研究中,我们设计了一种靶向整合素α5 (ITGA5)的环肽(cyAV3.3),以破坏cafa诱导的癌细胞间的粘连形成和串扰。在体外实验中,cyAV3.3抑制胰腺星状细胞向CAFs的分化,减少ECM的产生。在3D共培养的人类球体模型中,该肽降低了耐药标志物(ABCG1、BCL2、CXCR4)、干性标志物(WNT1、CD44)和ECM重塑标志物(COL1A1、MMP2/9、LOX),增强了吉西他滨的疗效。在体内,放射标记的cyAV3.3在共注射异种移植物肿瘤模型中,经肠外注射后表现出高的肿瘤积累和保留。有趣的是,cyAV3.3联合吉西他滨可提高吉西他滨在共注射异种移植物和基因工程LSL-KrasG12D/+ LSL-Trp53R172H/+ Pdx1-Cre (KPC) PDAC模型中的治疗效果。这些作用是由于减少了结缔组织增生、血管受压、增强了细胞毒性T细胞的浸润和凋亡。本研究提出了一种新的环状肽抑制itga5介导的肿瘤-基质相互作用,从而减少结缔组织增生和耐药性,最终提高PDAC的化疗疗效。
{"title":"Engineered cyclic peptide targeting ITGA5 disrupts tumor–stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma","authors":"Deby Fajar Mardhian ,&nbsp;Kunal P. Pednekar ,&nbsp;Ahmed G. Hemdan ,&nbsp;Praneeth Reddy Kuninty ,&nbsp;Saadia A. Karim ,&nbsp;Sabine de Winter ,&nbsp;Josbert M. Metselaar ,&nbsp;Jennifer P. Morton ,&nbsp;Jai Prakash","doi":"10.1016/j.apsb.2025.10.022","DOIUrl":"10.1016/j.apsb.2025.10.022","url":null,"abstract":"<div><div>The tumor–stroma interaction contributes to the aggressive and resistance nature of pancreatic ductal adenocarcinoma (PDAC), leading to treatment failure. Cancer-associated fibroblasts (CAFs), a key cell type in the stroma, produce abundant extracellular matrix (ECM) and exhibit crosstalk with cancer cells inducing chemoresistance. In this study, we designed a cyclic peptide (cyAV3.3) targeting integrin <em>α</em>5 (ITGA5) to disrupt CAF-induced desmoplasia and crosstalk with cancer cells. <em>In vitro</em>, cyAV3.3 inhibited the differentiation of pancreatic stellate cells into CAFs and reduced ECM production. In 3D co-cultured human spheroid models, the peptide decreased markers of resistance (ABCG1, BCL2, CXCR4), stemness (WNT1, CD44) and ECM remodeling (COL1A1, MMP2/9, LOX) and enhanced gemcitabine efficacy. <em>In vivo</em>, radiolabeled cyAV3.3 exhibited high tumor accumulation and retention following parenteral injections in a co-injection xenograft tumor model. Intriguingly, combination of cyAV3.3 with gemcitabine resulted in improved therapeutic efficacy of gemcitabine in co-injection xenograft and genetically engineered <em>LSL-Kras</em><sup>G12D/+</sup> <em>LSL-Trp53</em><sup>R172H/+</sup> <em>Pdx1-Cre</em> (KPC) PDAC models. These effects were attributed to reduced desmoplasia, vasculature compression and enhanced infiltration of cytotoxic T cells and apoptosis. This study presents a novel cyclic peptide inhibiting ITGA5-mediated tumor–stroma interaction and thereby reduce desmoplasia and resistance, ultimately enhancing chemotherapy efficacy in PDAC.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 1","pages":"Pages 305-321"},"PeriodicalIF":14.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145941467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
USP10-mediated deubiquitination and activation of KRAS mutants promotes colorectal cancer via a novel USP10/KRAS positive feedback circuit USP10介导的KRAS突变体的去泛素化和激活通过一种新的USP10/KRAS正反馈回路促进结直肠癌
IF 14.6 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01 Epub Date: 2025-11-13 DOI: 10.1016/j.apsb.2025.11.015
Tao Yuan , Weihua Wang , Ruilin Wu , Yue Liu , Junwei Fu , Jiamin Du , Meijia Qian , Jia’er Wang , Yubo Zhang , Wencheng Kong , Ronggui Hu , Tianhua Zhou , Qiaojun He , Bo Yang , Hong Zhu
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is associated with the poor prognosis of colorectal cancer (CRC) patients, but the therapeutic strategies targeting KRAS are limited, and novel intervention strategies are urgently needed. The dysfunction of deubiquitinases (DUBs) is widely involved in the progression of malignancy, and DUBs are considered ideal anti-tumor targets due to their well-defined structures and catalytic sites. In our study, through DUB inhibitors screening and liquid chromatography-tandem mass spectrometry (LC–MS/MS) analysis, we identified that ubiquitin-specific protease 10 (USP10) functions as a potent DUB regulating KRAS mutants' activity. Mechanistically, USP10 directly binds to and promotes KRAS variants' activity across different mutants by removing the latter’s non-proteolytic ubiquitination chains mainly containing K6, K11, K27 and K29-linkage; while the activated KRAS mutants reciprocally upregulate USP10 levels by phosphorylating the latter at Thr42/Ser337, therefore forming a positive feedback circuit and synergistically promoting KRAS-mutant CRC growth. Moreover, we found that USP10 is elevated in KRAS-mutant CRC tissues and depletion of USP10 preferentially impeded KRAS-mutant CRC growth in vitro/in vivo. Our findings not only uncover the critical roles of the USP10/KRAS positive feedback circuit in promoting KRAS-mutant CRC growth, but also offer novel therapeutic strategies for CRC patients harboring KRAS variants across different mutants by targeting USP10.
Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)突变与结直肠癌(CRC)患者预后不良有关,但针对KRAS的治疗策略有限,迫切需要新的干预策略。去泛素酶(deubiquitinases, DUBs)的功能障碍广泛参与恶性肿瘤的进展,由于DUBs具有明确的结构和催化位点,被认为是理想的抗肿瘤靶点。在我们的研究中,通过DUB抑制剂筛选和液相色谱-串联质谱(LC-MS /MS)分析,我们发现泛素特异性蛋白酶10 (USP10)作为一种有效的DUB调节KRAS突变体的活性。在机制上,USP10直接结合并促进KRAS变异体在不同突变体中的活性,通过去除后者主要含有K6、K11、K27和k29连锁的非蛋白水解泛素化链;而激活的KRAS突变体通过磷酸化USP10的Thr42/Ser337位点,相互上调USP10水平,从而形成一个正反馈回路,协同促进KRAS突变体CRC生长。此外,我们发现USP10在kras突变型CRC组织中升高,USP10的缺失优先阻碍了kras突变型CRC的体外/体内生长。我们的研究结果不仅揭示了USP10/KRAS正反馈回路在促进KRAS突变型结直肠癌生长中的关键作用,而且通过靶向USP10为不同突变型的KRAS变异体结直肠癌患者提供了新的治疗策略。
{"title":"USP10-mediated deubiquitination and activation of KRAS mutants promotes colorectal cancer via a novel USP10/KRAS positive feedback circuit","authors":"Tao Yuan ,&nbsp;Weihua Wang ,&nbsp;Ruilin Wu ,&nbsp;Yue Liu ,&nbsp;Junwei Fu ,&nbsp;Jiamin Du ,&nbsp;Meijia Qian ,&nbsp;Jia’er Wang ,&nbsp;Yubo Zhang ,&nbsp;Wencheng Kong ,&nbsp;Ronggui Hu ,&nbsp;Tianhua Zhou ,&nbsp;Qiaojun He ,&nbsp;Bo Yang ,&nbsp;Hong Zhu","doi":"10.1016/j.apsb.2025.11.015","DOIUrl":"10.1016/j.apsb.2025.11.015","url":null,"abstract":"<div><div>Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is associated with the poor prognosis of colorectal cancer (CRC) patients, but the therapeutic strategies targeting KRAS are limited, and novel intervention strategies are urgently needed. The dysfunction of deubiquitinases (DUBs) is widely involved in the progression of malignancy, and DUBs are considered ideal anti-tumor targets due to their well-defined structures and catalytic sites. In our study, through DUB inhibitors screening and liquid chromatography-tandem mass spectrometry (LC–MS/MS) analysis, we identified that ubiquitin-specific protease 10 (USP10) functions as a potent DUB regulating <em>KRAS</em> mutants' activity. Mechanistically, USP10 directly binds to and promotes <em>KRAS</em> variants' activity across different mutants by removing the latter’s non-proteolytic ubiquitination chains mainly containing K6, K11, K27 and K29-linkage; while the activated <em>KRAS</em> mutants reciprocally upregulate USP10 levels by phosphorylating the latter at Thr42/Ser337, therefore forming a positive feedback circuit and synergistically promoting <em>KRAS</em>-mutant CRC growth. Moreover, we found that USP10 is elevated in <em>KRAS</em>-mutant CRC tissues and depletion of USP10 preferentially impeded <em>KRAS</em>-mutant CRC growth <em>in vitro</em>/<em>in vivo</em>. Our findings not only uncover the critical roles of the USP10/KRAS positive feedback circuit in promoting <em>KRAS</em>-mutant CRC growth, but also offer novel therapeutic strategies for CRC patients harboring KRAS variants across different mutants by targeting USP10.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 1","pages":"Pages 322-336"},"PeriodicalIF":14.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145941468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Pharmaceutica Sinica. B
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1